Replimune Group's stock fell sharply, dropping about 84% from a high of $10.73 to $1.70 after the FDA rejected its RP1 biologics license application. The FDA cited insufficient data and study design concerns, which were not addressed despite prior communications. This led to a securities class action lawsuit alleging that investors were misled about the trial data and risks. Investors who bought shares between October 2025 and April 2026 may seek compensation by October 5, 2026.
The article explains three main Bitcoin bridge models—Custodial, Federated, and Smart Contract (Threshold)—each with different risk profiles and operational controls. Custodial bridges like WBTC offer broad liquidity but rely on a single custodian fo...
Alphabet is initiated with a Buy rating and a price target of $432, suggesting a 26% upside. This optimism is fueled by accelerating momentum in its Search business, AI-powered Gemini projects, and Google Cloud Platform (GCP). The company’s $200 bill...
Aptos (APT) surged over 10% in 24 hours, driven by a supply crunch following a 10x fee increase that funds token buybacks and burns. Over 1.5 million APT tokens were burned in the past month, reducing circulating supply and boosting network activity....
The Eldridge BBB-B CLO ETF (CLOZ) remains a recommended buy, providing an estimated 6.8% annual yield with monthly income distributions. It has shifted its portfolio towards higher-quality BBB CLOs to reduce risk, though it has underperformed peers y...
Zcash (ZEC) surged to an intraday high of $979, marking an 88.1% gain over the past 30 days and a 353% rise over six months. This price increase has driven the network's hashrate to 91% of its all-time high, reflecting a significant influx of mining ...
